secwatch.observer — SEC 8-K summary
======================================

Issuer:     Glucotrack, Inc. (GCTK)
CIK:        0001506983
Form:       8-K
Filed at:   2026-07-30T21:29:16+00:00
Accession:  0001493152-26-035503
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Glucotrack subsidiary Lokahi advances LT-100 to single-injection strategy after FDA meeting
--------------------------------------------------------------------------------

- Lokahi Therapeutics (GCTK subsidiary) plans to simplify LT-100 from 15 intradermal injections to a single subcutaneous injection per visit.
- Type C meeting with FDA in May 2026 supported the proposed clinical strategy for LT-100.
- Nonclinical minipig study showed subcutaneous administration achieved systemic exposure consistent with prior intradermal data.
- Clinical evaluation of single-injection approach expected to begin as early as Q4 2026, with initial readout in H1 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1506983/000149315226035503/0001493152-26-035503-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1506983/000149315226035503/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-035503

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer